Skip to content
Screener

Journey Medical Corporation DERM EV / EBITDA

EV / EBITDA at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
12×+3.9×
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
32.5×—
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
125.8×—
HRO
HarrowHROW
70.8×-139×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
1,820.6×—
VAT
InnovateVATE
20.5×+2.4×

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M—
Free cash flow-$6.0M—

Valuation

See full
Market cap$179.8M+6.8%
Enterprise value$178.05M+2.7%
P/S2.8×-0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%—
Net margin-14.8%—
FCF margin-43%—

Returns & leverage

See full
Return on equity-36.6%—
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Calculated from Journey Medical Corporation’s reported figures.

enterprise value/ebitda=19.9×

Based on the most recent quarter.

The source filing: Journey Medical Corporation’s 10-Q, filed August 13, 2024. Open the filing →

Filed
Aug 13, 2024
Fiscal quarter
Q2 FY2024
Calendar quarter
Q2 2024
Accession
0001410578-24-001326

FAQ

What is Journey Medical Corporation's EV / EBITDA?
Journey Medical Corporation (DERM) reported EV / EBITDA of 19.9× in Q2 2024.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Journey Medical Corporation's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude